Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Syndax Announces Participation in Upcoming Investor Conferences GlobeNewswire - Wed May 20, 6:00AM CDT

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger,...

SNDX : 20.09 (+3.77%)
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition GlobeNewswire - Tue May 12, 9:31AM CDT

– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerability...

SNDX : 20.09 (+3.77%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Wed May 6, 3:01PM CDT

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2026,...

SNDX : 20.09 (+3.77%)
Syndax: Q1 Earnings Snapshot AP - Thu Apr 30, 3:22PM CDT

Syndax: Q1 Earnings Snapshot

SNDX : 20.09 (+3.77%)
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire - Thu Apr 30, 3:01PM CDT

– Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition...

SNDX : 20.09 (+3.77%)
Syndax: When Does the Revenue Ramp Start Covering the Cash Burn Story? Barchart - Wed Apr 29, 4:22PM CDT

Barchart Research What to Expect from SNDX Earnings SNDX Generated April 29, 2026 Current Price $20.63 EPS Estimate $$-0.58 Consensus Rating Strong Buy Average Move 10.13% Syndax: When Does the Revenue...

SNDX : 20.09 (+3.77%)
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 GlobeNewswire - Fri Apr 24, 6:00AM CDT

NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report...

SNDX : 20.09 (+3.77%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Fri Apr 3, 3:01PM CDT

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1,...

SNDX : 20.09 (+3.77%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Wed Mar 4, 3:01PM CST

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March 1,...

SNDX : 20.09 (+3.77%)
Syndax: Q4 Earnings Snapshot AP - Thu Feb 26, 4:02PM CST

Syndax: Q4 Earnings Snapshot

SNDX : 20.09 (+3.77%)

Barchart Exclusives

Medicare Advantage Company Alignment Healthcare Shows Huge, Unusual Call Option Activity Barchart - 4 minutes ago
Alignment Healthcare, a fast-growing Medicare Advantage company, had strong Q1 revenue and adjusted EBITDA results. That may be the underlying reason for the huge, unusual call option activity today. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.